Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATL in HCC Patients After Curative Treatment
NCT05304481Phase 2Recruiting
- Sponsor
- Lukas Biomedical
- Start
- May 2022
- Primary completion
- Dec 2027
- Modality
- Allogeneic CAR-T, Tumor-Infiltrating Lymphocytes (TILs), TCR-Engineered T Cells
- Countries
- 1
01
Overview
A Phase 2 trial of LuLym-T in hepatocellular carcinoma (HCC), sponsored by Lukas Biomedical. Started May 2022; status: recruiting.
02
Drugs
LuLym-T
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT05304481.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05304481.